Proteasome inhibitors for multiple myeloma

被引:43
作者
Okazuka, Kiyoshi [1 ]
Ishida, Tadao [1 ]
机构
[1] Japanese Red Cross Med Ctr, Dept Hematol, 4-1-22 Hiroo, Shibuya, Tokyo 1508935, Japan
关键词
multiple myeloma; proteasome inhibitor; bortezomib; carfilzomib; ixazomib; BORTEZOMIB-MELPHALAN-PREDNISONE; PHASE-III TRIAL; INITIAL TREATMENT; RENAL IMPAIRMENT; IN-VITRO; PLUS BORTEZOMIB; ORAL IXAZOMIB; SINGLE-AGENT; OPEN-LABEL; DEXAMETHASONE;
D O I
10.1093/jjco/hyy108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Therapeutic strategies for multiple myeloma have dramatically changed in the last two decades, especially after the introduction of proteasome inhibitors. The first-in-class proteasome inhibitor, bortezomib, was approved by the US Food and Drug Administration in 2003. Since then, it has been a backbone therapy for not only relapsed or refractory myeloma patients but also newly diagnosed multiple myeloma patients. Second-generation proteasome inhibitors, such as carfilzomib and ixazomib, have been approved, and three proteasome inhibitors were incorporated into several regimens with other cytotoxic agents, such as alkylating agents, immunomodulatory drugs and monoclonal antibodies. Because each proteasome inhibitor shows different properties with respect to adverse events, understanding and managing each adverse event of proteasome inhibitors are necessary for the continuation of therapy with minimal interruption of treatment. This review summarizes the recent advances in proteasome inhibitors used in the treatment of multiple myeloma.
引用
收藏
页码:785 / 792
页数:8
相关论文
共 54 条
[1]   The proteasome: A suitable antineoplastic target [J].
Adams, J .
NATURE REVIEWS CANCER, 2004, 4 (05) :349-360
[2]   Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].
Attal, Michel ;
Lauwers-Cances, Valerie ;
Hulin, Cyrille ;
Leleu, Xavier ;
Caillot, Denis ;
Escoffre, Martine ;
Arnulf, Bertrand ;
Macro, Margaret ;
Belhadj, Karim ;
Garderet, Laurent ;
Roussel, Murielle ;
Payen, Catherine ;
Mathiot, Claire ;
Fermand, Jean P. ;
Meuleman, Nathalie ;
Rollet, Sandrine ;
Maglio, Michelle E. ;
Zeytoonjian, Andrea A. ;
Weller, Edie A. ;
Munshi, Nikhil ;
Anderson, Kenneth C. ;
Richardson, Paul G. ;
Facon, Thierry ;
Avet-Loiseau, Herve ;
Harousseau, Jean-Luc ;
Moreau, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320
[3]   Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients [J].
Avet-Loiseau, Herve ;
Bahlis, Nizar J. ;
Chng, Wee-Joo ;
Masszi, Tamas ;
Viterbo, Luisa ;
Pour, Ludek ;
Ganly, Peter ;
Palumbo, Antonio ;
Cavo, Michele ;
Langer, Christian ;
Pluta, Andrzej ;
Nagler, Arnon ;
Kumar, Shaji ;
Ben-Yehuda, Dina ;
Rajkumar, S. Vincent ;
San-Miguel, Jesus ;
Berg, Deborah ;
Lin, Jianchang ;
van de Velde, Helgi ;
Esseltine, Dixie-Lee ;
di Bacco, Alessandra ;
Moreau, Philippe ;
Richardson, Paul G. .
BLOOD, 2017, 130 (24) :2610-2618
[4]   Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety [J].
Badros, A. Z. ;
Vij, R. ;
Martin, T. ;
Zonder, J. A. ;
Kunkel, L. ;
Wang, Z. ;
Lee, S. ;
Wong, A. F. ;
Niesvizky, R. .
LEUKEMIA, 2013, 27 (08) :1707-1714
[5]   CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma [J].
Berenson, James R. ;
Cartmell, Alan ;
Bessudo, Alberto ;
Lyons, Roger M. ;
Harb, Wael ;
Tzachanis, Dimitrios ;
Agajanian, Richy ;
Boccia, Ralph ;
Coleman, Morton ;
Moss, Robert A. ;
Rifkin, Robert M. ;
Patel, Priti ;
Dixon, Sandra ;
Ou, Ying ;
Anderl, Janet ;
Aggarwal, Sanjay ;
Berdeja, Jesus G. .
BLOOD, 2016, 127 (26) :3360-3368
[6]   Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment [J].
Blade, Joan ;
Sonneveld, Pieter ;
Miguel, Jesus E. San ;
Sutherland, Heather J. ;
Hajek, Roman ;
Nagler, Arnon ;
Spencer, Andrew ;
Robak, Tadeusz ;
Cibeira, M. Teresa ;
Zhuang, Sen H. ;
Harousseau, Jean-Luc ;
Orlowski, Robert Z. .
CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (06) :352-355
[7]   Efficacy and safety of once-weekly bortezomib in multiple myeloma patients [J].
Bringhen, Sara ;
Larocca, Alessandra ;
Rossi, Davide ;
Cavalli, Maide ;
Genuardi, Mariella ;
Ria, Roberto ;
Gentili, Silvia ;
Patriarca, Francesca ;
Nozzoli, Chiara ;
Levi, Anna ;
Guglielmelli, Tommasina ;
Benevolo, Giulia ;
Callea, Vincenzo ;
Rizzo, Vincenzo ;
Cangialosi, Clotilde ;
Musto, Pellegrino ;
De Rosa, Luca ;
Liberati, Anna Marina ;
Grasso, Mariella ;
Falcone, Antonietta P. ;
Evangelista, Andrea ;
Cavo, Michele ;
Gaidano, Gianluca ;
Boccadoro, Mario ;
Palumbo, Antonio .
BLOOD, 2010, 116 (23) :4745-4753
[8]   In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells [J].
Chauhan, Dharminder ;
Tian, Ze ;
Zhou, Bin ;
Kuhn, Deborah ;
Orlowski, Robert ;
Raje, Noopur ;
Richardson, Paul ;
Anderson, Kenneth C. .
CLINICAL CANCER RESEARCH, 2011, 17 (16) :5311-5321
[9]   A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma [J].
Chauhan, Dharminder ;
Singh, Ajita V. ;
Aujay, Monette ;
Kirk, Christopher J. ;
Bandi, Madhavi ;
Ciccarelli, Bryan ;
Raje, Noopur ;
Richardson, Paul ;
Anderson, Kenneth C. .
BLOOD, 2010, 116 (23) :4906-4915
[10]   Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR [J].
Chng, W-J ;
Goldschmidt, H. ;
Dimopoulos, M. A. ;
Moreau, P. ;
Joshua, D. ;
Palumbo, A. ;
Facon, T. ;
Ludwig, H. ;
Pour, L. ;
Niesvizky, R. ;
Oriol, A. ;
Rosinol, L. ;
Suvorov, A. ;
Gaidano, G. ;
Pika, T. ;
Weisel, K. ;
Goranova-Marinova, V. ;
Gillenwater, H. H. ;
Mohamed, N. ;
Feng, S. ;
Aggarwal, S. ;
Hajek, R. .
LEUKEMIA, 2017, 31 (06) :1368-1374